Gemcitabine plus paclitaxel (GT) versus paclitaxel (T) as first-line treatment for anthracycline pre-treated metastatic breast cancer (MBC): Quality of life (QoL) and pain palliation results from the global phase III study.

被引：0
|
作者：
Moinpour, C
Wu, J
Donaldson, G
Liepa, A
Melemed, A
Oshaughnessy, J
Rappold, E
Albain, K
机构：
[1] SW Oncol Grp, Ctr Stat, Seattle, WA USA
[2] Eli Lilly & Co, Indianapolis, IN 46285 USA
[3] Univ Utah, Salt Lake City, UT 84112 USA
[4] US Oncol Res Inc, Dallas, TX USA
[5] Loyola Univ, Med Ctr, Maywood, IL 60153 USA
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2004年 / 22卷 / 14期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
621
引用
收藏
页码：32S / 32S
页数：1
相关论文
共 50 条
  • [31] The efficacy and safety of Nab-paclitaxel plus gemcitabine versus mFOLFIRINOX in the first-line treatment of metastatic pancreatic cancer: a retrospective study
    Yang, Lei
    Su, Jing
    Wang, Wenbo
    Zhou, Fuxiang
    WORLD JOURNAL OF SURGICAL ONCOLOGY, 2023, 21 (01)
  • [32] Infusional 5-fluorouracil/leucovorin plus paclitaxel and cisplatin in the first-line treatment of metastatic breast cancer: Results of a phase II study
    Klaassen, U
    Wilke, H
    Muller, C
    Borquez, D
    Harstrick, A
    Seeber, S
    SEMINARS IN ONCOLOGY, 1997, 24 (05) : 58 - 60
  • [33] A phase I study of sunitinib plus paclitaxel for first-line treatment of advanced breast cancer: preliminary results.
    Kozloff, M. F.
    Chuang, E.
    Roy, J.
    Starr, A.
    Gowland, P. A.
    Tarpey, M. J.
    Coliler, M.
    Verk, L.
    Kern, K.
    Miller, K.
    BREAST CANCER RESEARCH AND TREATMENT, 2007, 106 : S273 - S273
  • [34] QUALITY OF LIFE (QOL) AMONG PATIENTS (PTS) WITH LOCALLY RECURRENT (LR) OR METASTATIC BREAST CANCER (MBC): RESULTS FROM THE PHASE III AVADO STUDY OF FIRST-LINE BEVACIZUMAB (BV) PLUS DOCETAXEL (D) VERSUS D PLUS PLACEBO (PL)
    Greil, R.
    Im, Y. H.
    Pienkowski, T.
    Wardley, A.
    Awada, A.
    Ciruelos, E.
    Freitas-Junior, R.
    Fumoleau, P.
    Sriuranpong, V.
    Miles, D. W.
    ANNALS OF ONCOLOGY, 2008, 19 : 67 - 67
  • [35] INTERIM RESULTS OF A PHASE II STUDY OF NAB-PACLITAXEL, BEVACIZUMAB, AND GEMCITABINE AS FIRST-LINE THERAPY FOR PATIENTS WITH HER2-NEGATIVE METASTATIC BREAST CANCER (MBC)
    Gluck, S.
    Lobo, C.
    Hurley, J.
    Lopes, G.
    Reis, I.
    Seo, P.
    Silva, O.
    Slingerland, J.
    Welsh, C.
    Tukia, K.
    ANNALS OF ONCOLOGY, 2008, 19 : 68 - 69
  • [36] Epirubicin/paclitaxel (EP) vs. capecitabine/paclitaxel (XP) in first-line metastatic breast cancer (MBC):: A prospective, randomized multicentre phase III study of the AGO breast cancer study group.
    Lueck, H.
    Minckwitz, G. V.
    Du Bois, A.
    Schrader, I.
    Huober, J.
    Heilmann, V.
    Beckmann, M.
    Stähle, A.
    Jackisch, C.
    Marth, C.
    Richter, B.
    JOURNAL OF CLINICAL ONCOLOGY, 2006, 24 (18) : 7S - 7S
  • [37] Randomized multicenter phase III study of epirubicin/paclitaxel versus epirubicin/cyclophosphamide in first-line treatment of metastatic breast cancer:: A study of the AGO Breast Cancer Study Group
    Lück, HJ
    Thomssen, C
    Kuhn, W
    Eidtmann, H
    du Bois, A
    Möbus, V
    Untch, M
    Jackisch, C
    Olbricht, S
    Schröder, W
    Richter, B
    Bauknecht, T
    Köhler, C
    Schulz, R
    von Minckwitz, G
    Blohmer, J
    SEMINARS IN ONCOLOGY, 1999, 26 (06) : 8 - 8
  • [38] Phase II, multicentre, randomised trial of eribulin plus gemcitabine versus paclitaxel plus gemcitabine as first-line chemotherapy in patients with HER2-negative metastatic breast cancer
    Park, Yeon Hee
    Im, Seock-Ah
    Kim, Sung-Bae
    Sohn, Joo Hyuk
    Lee, Keun Seok
    Chae, Yee Soo
    Lee, Ki Hyeong
    Kim, Jee Hyun
    Im, Young-Hyuck
    Kim, Ji-Yeon
    Kim, Tae-Yong
    Lee, Kyung-Hun
    Ahn, Jin-Hee
    Kim, Gun Min
    Park, In Hae
    Lee, Soo Jung
    Han, Hye Sook
    Kim, Se Hyun
    Jung, Kyung Hae
    EUROPEAN JOURNAL OF CANCER, 2017, 86 : 385 - 393
  • [39] Phase II study of nab-paclitaxel, bevacizumab, and gemcitabine for first-line therapy of patients with HER2-negative metastatic breast cancer (MBC)
    Gluck, S.
    Lobo, C.
    Reis, I.
    Lopes, G.
    Carmody, C.
    Tukia, K.
    Hurley, J.
    Seo, P.
    Silva, O.
    Slingerland, J.
    Welsh, C.
    JOURNAL OF CLINICAL ONCOLOGY, 2008, 26 (15)
  • [40] Phase III, Double-Blind, Randomized Study Comparing Lapatinib Plus Paclitaxel With Placebo Plus Paclitaxel As First-Line Treatment for Metastatic Breast Cancer (vol 26, pg 5544, 2008)
    Leo, Di
    JOURNAL OF CLINICAL ONCOLOGY, 2009, 27 (11) : 1923 - 1923
12345